Skip to main content
. 2014 Autumn;8(4):18–27.

Table 3.

Incidence of Adverse Effects During the Ddouble-blind Phase for the Treatment Groups

Adverse effect Cinnarizine
(N = 20)
n(%)
Topiramate
(N = 20)
n(%)
Mild sedation 4 (20) 5 (25)
Sever sedation 0 (0) 0 (0)
Mild appetite decrease 0 (0) 1 (5)
Sever appetite decrease 0 (0) 1 (5)
Weight loss 0 (0) 1 (5)